NCT02947620

Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)

A Multi-center, Randomized, Double-blind, Active-controlled, Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 185 (actual)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A Multi-center, Randomized, double-blind, active-controlled, phase 3 trial to evaluate the safety and efficacy of Metformin/Atorvastatin in subjects with Type II Diabetes and dyslipidemia.

Conditions

• Type II Diabetes
• Dyslipidemia

Interventions

Type	Name	Description
DRUG	Metformin/Atorvastatin 1500mg/40mg, QD
DRUG	Metformin 1500mg, QD
DRUG	Atorvastatin 40mg, QD

Timeline

• Start date: 2015-08-01
• Primary completion: 2017-02-27
• Completion: 2017-02-27
• First posted: 2016-10-28
• Last updated: 2023-06-18

Locations

1 site across 1 country: South Korea